

Francesco Carubbi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8118658/publications.pdf>

Version: 2024-02-01

109
papers

3,271
citations

136950

32
h-index

175258

52
g-index

109
all docs

109
docs citations

109
times ranked

4496
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. <i>Autoimmunity Reviews</i> , 2011, 10, 595-598.	5.8	168
2	The Role of IL-1 β in the Bone Loss during Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	146
3	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	3.5	143
4	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	5.5	130
5	Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. <i>Journal of Autoimmunity</i> , 2014, 51, 75-80.	6.5	126
6	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis), <i>TJ ETQq0 0 0 rgBT/Overlock 10 Tf 50 5</i>	5.8	107
7	Methotrexate: an old new drug in autoimmune disease. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1519-1530.	3.0	100
8	2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 61-68.	0.9	84
9	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. <i>Journal of Rheumatology</i> , 2015, 42, 1808-1816.	2.0	82
10	Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. <i>Autoimmunity Reviews</i> , 2015, 14, 1019-1022.	5.8	80
11	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	3.0	76
12	Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. <i>Scientific Reports</i> , 2021, 11, 4863.	3.3	73
13	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	5.8	65
14	Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. <i>RMD Open</i> , 2020, 6, e001295.	3.8	65
15	Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. <i>Frontiers in Medicine</i> , 2018, 5, 102.	2.6	64
16	Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. <i>Current and Emerging Paradigms. Clinical Therapeutics</i> , 2014, 36, 427-435.	2.5	62
17	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	3.4	61
18	CD4 ⁺ CD8 ⁻ T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. <i>Journal of Autoimmunity</i> , 2014, 51, 38-43.	6.5	60

#	ARTICLE	IF	CITATIONS
19	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	59
20	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clinical Rheumatology, 2017, 36, 2839-2845.	2.2	53
21	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmunity Reviews, 2015, 14, 429-437.	5.8	46
22	IL-1 β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. Expert Review of Clinical Immunology, 2016, 12, 849-855.	3.0	46
23	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. Journal of Rheumatology, 2016, 43, 1340-1349.	2.0	45
24	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. Medicine (United States), 2017, 96, e7896.	1.0	42
25	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS ONE, 2017, 12, e0181203.	2.5	42
26	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology, 2014, 53, 1313-1320.	1.9	41
27	Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligenceâ€“radiological differences. Annals of the Rheumatic Diseases, 2020, 79, 1152-1155.	0.9	41
28	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS ONE, 2017, 12, e0170108.	2.5	41
29	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.9	37
30	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?. Autoimmunity Reviews, 2014, 13, 1167-1173.	5.8	36
31	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. Expert Review of Clinical Immunology, 2017, 13, 1041-1047.	3.0	36
32	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes. Medicine (United States), 2019, 98, e14587.	1.0	36
33	Post-Translational Modifications of Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. Cells, 2019, 8, 657.	4.1	34
34	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. Rheumatology International, 2020, 40, 951-958.	3.0	34
35	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. Journal of Rheumatology, 2017, 44, 1179-1183.	2.0	33
36	Safety and efficacy of intra-articular anti-tumor necrosis factor β agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. International Journal of Immunopathology and Pharmacology, 2016, 29, 252-266.	2.1	32

#	ARTICLE	IF	CITATIONS
37	Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. <i>BioMed Research International</i> , 2017, 2017, 1-8.	1.9	31
38	Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 81.	4.7	31
39	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 782-783.	0.9	29
40	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1727-1737.	3.1	29
41	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 223.	3.5	29
42	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 123.	0.8	28
43	Myositis in primary Sjogren's syndrome: data from a multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 457-64.	0.8	27
44	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. <i>Journal of Autoimmunity</i> , 2020, 108, 102397.	6.5	26
45	The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 210-214.	0.8	26
46	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.9	26
47	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, 13.	3.4	24
48	Childhood-onset of primary Sjogren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , 2021, 60, 4558-4567.	1.9	24
49	Interferon gamma-inducible protein 16 in primary Sjogren's syndrome: a novel player in disease pathogenesis?. <i>Arthritis Research and Therapy</i> , 2015, 17, 208.	3.5	23
50	Macitentan inhibits the transforming growth factor- β 2 profibrotic action, blocking the signaling mediated by the ETR/T β RI complex in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2015, 17, 247.	3.5	22
51	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , 2017, 36, 251-260.	2.2	22
52	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. <i>Modern Rheumatology</i> , 2018, 28, 922-932.	1.8	21
53	The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. <i>Frontiers in Medicine</i> , 2018, 5, 290.	2.6	20
54	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	2.2	20

#	ARTICLE	IF	CITATIONS
55	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 540.	2.4	20
56	Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID?. <i>Viruses</i> , 2021, 13, 1997.	3.3	20
57	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.7	19
58	Respiratory Manifestations in Systemic Lupus Erythematosus. <i>Pharmaceuticals</i> , 2021, 14, 276.	3.8	19
59	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 441-452.	3.0	18
60	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , 2019, 9, 7144.	3.3	18
61	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicines</i> , 2021, 9, 671.	3.2	17
62	The URRAH study. <i>Panminerva Medica</i> , 2021, 63, .	0.8	16
63	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	1.9	15
64	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
65	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. <i>Scientific Reports</i> , 2019, 9, 4589.	3.3	12
66	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 119-128.	3.0	12
67	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 615656.	4.8	12
68	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1640-1646.	0.9	12
69	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , 2019, 14, e0211142.	2.5	11
70	Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know?. <i>BMC Rheumatology</i> , 2020, 4, 51.	1.6	10
71	Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. <i>Journal of Rheumatology</i> , 2021, 48, 179-187.	2.0	9
72	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 192-198.	0.8	9

#	ARTICLE	IF	CITATIONS
73	EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 760-767.	0.9	9
74	The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. <i>Frontiers in Medicine</i> , 2020, 7, 608728.	2.6	8
75	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. <i>Archives of Medical Science</i> , 2016, 4, 828-843.	0.9	7
76	The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e42-e42.	0.9	6
77	Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide. <i>Medicine (United Tj ETQq1 1 Q.784314 ggBT /Over</i>	1.0	6
78	Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting. <i>Frontiers in Medicine</i> , 2020, 7, 534.	2.6	6
79	Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?. <i>Nutrients</i> , 2021, 13, 772.	4.1	6
80	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. <i>Current Rheumatology Reviews</i> , 2018, 15, 27-43.	0.8	6
81	Novel insights on lymphoma and lymphomagenesis in primary Sjögren's Syndrome. <i>Panminerva Medica</i> , 2021, 63, .	0.8	6
82	Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001864.	3.8	6
83	Adherence to the Mediterranean diet and the impact on clinical features in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 190-196.	0.8	6
84	Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives. <i>RMD Open</i> , 2017, 3, e000514.	3.8	5
85	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 692-697.	2.2	5
86	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5
87	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1123-1124.	0.8	4
88	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 277-291.	1.4	3
89	The challenge to interpret conflicting results and the need of a univocal definition for germinal centres in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212108.	0.9	3
90	The Serological Status Affects the Prognostic Role of Salivary Gland Histology in Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2020, 47, 1838-1838.	2.0	3

#	ARTICLE	IF	CITATIONS
91	Blood Pressure Profiles and Cognitive Function from Adulthood to Old Age: Chasing a Golden Middle Way?. <i>Journal of Clinical Medicine</i> , 2021, 10, 3243.	2.4	3
92	Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. <i>Frontiers in Medicine</i> , 2021, 8, 779975.	2.6	3
93	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 546-547.	0.8	3
94	Novel Therapeutic Strategies in Primary Sjögren's Syndrome. <i>Israel Medical Association Journal</i> , 2017, 19, 576-580.	0.1	3
95	Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 133-139.	0.8	3
96	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 73-79.	0.8	2
97	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2
98	Response to: "Correspondence on Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence radiological differences" by Ruscitti et al. by Chen et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e221-e221.	0.9	1
99	Advancing frontiers in rheumatic and musculoskeletal imaging. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 227.	1.9	1
100	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 938-946.	0.8	1
101	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
102	Relevance of Interferon-Inducible Protein 16 Rather than Anti-Interferon-Inducible Protein 16 Autoantibodies as a Clinical and Pathogenic Biomarker in Primary Sjögren's Syndrome: Comment on the Article by Baer et al. <i>Arthritis Care and Research</i> , 2017, 69, 453-454.	3.4	0
103	Different clinical presentations of primary Sjögren's syndrome: Not only a matter of age. Comment on: "Elderly-onset primary Sjögren's syndrome focused on clinical and salivary gland ultrasonographic features by Lee et al. <i>Joint Bone Spine</i> . 2021;88:105132. <i>Joint Bone Spine</i> , 2021, 88, 105191.	1.6	0
104	Editorial: Management of Sjögren's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 836182.	2.6	0
105	Characterisation of articular manifestations in primary Sjögren's syndrome: clinical and imaging features. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 166-173.	0.8	0
106	Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 53-56.	0.8	0
107	Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in Sjögren's syndrome and rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
108	Adherence to the Mediterranean diet and the impact on clinical features in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0

#	ARTICLE	IF	CITATIONS
109	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	3.4	0